BAHAREH TAHRIRI: Open Payments
NPI 1295147387 · SAN MARCOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$482 in 21 payments from 8 companies in 2025. Trend: 2023 $464 · 2024 $775 · 2025 $482
Food & beverage: $482
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 4 | $113 |
| Lilly USA, LLC | 4 | $78 |
| GlaxoSmithKline, LLC. | 3 | $77 |
| Xeris Pharmaceuticals, Inc. | 4 | $76 |
| ABBVIE INC. | 2 | $58 |
| SCILEX PHARMACEUTICALS INC. | 2 | $40 |
| Novo Nordisk Inc | 1 | $26 |
| ViiV Healthcare Company | 1 | $15 |
Products named: REZDIFFRA, MOUNJARO, GVOKE HYPOPEN, SHINGRIX, ELYXYB - CELECOXIB, TRELEGY ELLIPTA, UBRELVY, QULIPTA.
Industry payments across CA — which companies pay providers there.
